Policy Summary
PayerCommonwealth Care Alliance
PolicyPharmacy Drug Prior Authorization Criteria
Policy CodePolicy N/A
Change TypeNo material change
Effective DateN/A
Next Review DateN/A
Key ActionSubmit the requested indication and drug-specific clinical documentation for prior authorization.
For AD, asthma, EoE, COPD, BP, AFRS, PN, and CSU continuation, the patient must have achieved or maintained clinical benefit. Age limits vary by indication from 6 months for AD to 18 years for COPD, BP, and PN.
Amitriptyline for insomnia requires contraindication to doxepin 3 or 6 mg and ramelteon, or failure or intolerance of one; the prescriber must acknowledge risk and address CNS polypharmacy.
Octreotide for acromegaly requires elevated pretreatment IGF-1 and inadequate or partial response to surgery/radiotherapy or a clinical reason those treatments were not performed; continuation requires decreased or normalized IGF-1.
Ofev for idiopathic pulmonary fibrosis requires exclusion of other causes and UIP or multidisciplinary-supported diagnosis; progressive fibrosing ILD requires confirmed progression, and systemic-sclerosis ILD requires HRCT confirmation.
Rydapt for AML requires FLT3 mutation-positive disease; FGFR1 or FLT3 rearranged neoplasms must be in chronic or blast phase.
Biomarker confirmation: ALK, BRAF, EGFR, FGFR2, HER2/ERBB2, KRAS G12C, RET, NTRK, BRCA, IDH2, FLT3, FGFR1, KIT, PIK3CA, PDGFRA, PDGFRB, or other product-specific alteration.
Laboratory confirmation: platelet count, hemoglobin, ferritin, IGF-1, eosinophil count, pulmonary hemodynamics, HCV RNA, cystine, enzyme activity, or disease-specific autoantibodies.
Clinical or imaging confirmation: biopsy, HRCT, MRI, CT, polysomnography, sleep-lab evaluation, bone-age assessment, wound assessment, or documented disease manifestations.
Age and specialist restrictions
Age restrictions include Benlysta age 5 years or older, Dupixent indication-specific minimum ages, Eucrisa age 3 months or older, Increlex age 2 years or older, Icatibant age 18 years or older, Posaconazole age 2 years or older, and Pyzchiva and oncology products subject to their listed indication requirements.
Specialist involvement is required for products such as Berinert, Icatibant, Increlex, Northera when specified, and other disease-specific therapies when the policy requires immunology, allergy, rheumatology, endocrinology, oncology, pulmonology, gastroenterology, hepatology, neurology, or transplant consultation.
Procrit reauthorization requires at least 12 weeks of erythropoietin therapy, response, current hemoglobin below 12 g/dL, and adequate iron stores when required.
Pomalyst, Rubraca, Rydapt, oncology products, and biologics require ongoing disease-specific benefit and continued adherence to the approved regimen and sequencing requirements.
Clorazepate: For anxiety, require concurrent SSRI/SNRI therapy until effective or inadequate response, intolerance, or contraindication to at least two SSRIs/SNRIs. For patients 65 or older, apply the specified short-term, anxiety, or plan-year duration and document the older-adult risk review.Emsam and other prerequisite-therapy requests: Document required alternative antidepressant trials or contraindications before approval. Fetzima requires inadequate response, intolerance, or contraindication to two alternatives; Fanapt requires antipsychotic step therapy; and quetiapine XR requires generic alternatives and review of concurrent CNS medications.Ensacove and oncology biomarker criteria: For ALK-positive NSCLC, document recurrent, advanced, metastatic, or qualifying adjuvant disease and ALK positivity. Similar oncology requests require the applicable biomarker, stage, regimen, and prior-treatment documentation; insufficient biomarker or prior-therapy evidence, or a missing oncology regimen, supports denial.Eprontia, Ergotamine, and migraine therapy: Document required step therapy and alternatives. Ergotamine or dihydroergotamine requires prior triptan therapy and is denied with potent CYP3A4 inhibitors; migraine preventive products must not be combined with another CGRP antagonist.Erivedge and Erleada: Document the qualifying oncology diagnosis, disease status, biomarker or androgen-receptor indication, and required androgen-deprivation therapy where applicable. Missing androgen-deprivation therapy is a denial risk.Etanercept, Eucrisa, and topical therapy: Document required prerequisite therapy, including appropriate conventional or topical treatment trials, inadequate response, intolerance, or contraindication.Exxua and Fanapt: Document the qualifying diagnosis and required antipsychotic or antidepressant alternatives. Fanapt requires prior antipsychotic step therapy unless an alternative is contraindicated or not clinically appropriate.Fentanyl patch and extended-release opioids: Require a qualifying indication such as cancer, sickle-cell disease, terminal illness, palliative care, or severe persistent pain requiring extended opioid therapy. Document prior opioid exposure, safe dosing, opioid-use-disorder evaluation and monitoring, and either at least 30 days of prior extended-release opioid therapy or at least 1 week of immediate-release opioid therapy. Immediate-release therapy is required before extended-release therapy when specified.Fycompa: For partial-onset seizures, require inadequate response, intolerance, or contraindication to a generic anticonvulsant and to Aptiom, Xcopri, or Spritam. For primary generalized tonic-clonic seizures, require a generic anticonvulsant and Spritam alternative review.HER2-directed therapy: Document HER2-positive or HER2-amplified disease, applicable RAS/BRAF status, indication, combination regimen, and prior HER2-inhibitor history. Trastuzumab biosimilar substitution, including KANJINTI and related products, requires an intolerable adverse event to Trazimera not attributed to the active ingredient; Part D denial applies when Part A/B covers administration.High-risk medication authorization: Apply age and cumulative-duration limits, required alternative therapy, prescriber acknowledgment, and medication-burden review. Deny or pend when high-risk criteria are not met, the patient is below the applicable age threshold, or the duration exceeds the permitted limit without justification.Insulin pumps and supplies: For pump eligibility, document insulin-requiring diabetes, glucose self-testing, counseling or continuous glucose monitoring, and inadequate control or difficulty with multiple bolus injections. Insulin supplies require documentation that the product is used with insulin.CFTR potentiator restrictions: Alyftrek and Kalydeco may not be used with another CFTR potentiator, including ivacaftor or deutivacaftor. Avoid duplicate CFTR potentiator therapy; concurrent use is a denial condition.Mavyret: Exclude moderate or severe hepatic impairment or decompensated cirrhosis (Child-Pugh B or C). Document HCV RNA, genotype, treatment history, cirrhosis status, HIV status, resistance substitutions when applicable, transplant status, and the planned AASLD-IDSA-consistent regimen.Mepron: For PCP treatment, require intolerance or contraindication to sulfamethoxazole/trimethoprim. For PCP or primary toxoplasmosis prophylaxis, also document immunocompromised status; for babesiosis, document concurrent azithromycin.Koselugo, central precocious puberty, and age limits: Koselugo for neurofibromatosis type 1 requires age 1 year or older. Central precocious puberty requires qualifying GnRH/LH testing, bone-age assessment, and onset before age 8 in females or 9 in males; coverage is limited to females under 12 and males under 13. Memantine PA applies only to patients younger than 30.Lapatinib: Document HER2-positive breast cancer and combination with an aromatase inhibitor, capecitabine, or trastuzumab. For colorectal cancer, document HER2 amplification, RAS/BRAF wild-type status, combination with trastuzumab, and no prior HER2 inhibitor.Posaconazole prophylaxis: Document oral use, prophylaxis indication, weight greater than 40 kg, and age 2 years or older; insufficient prophylaxis documentation is a denial risk.Pregabalin: For oral solution, document difficulty swallowing solid dosage forms. For diabetic neuropathy or postherpetic neuralgia, document inadequate response, intolerance, or contraindication to generic gabapentin; the HRM restriction applies to patients 65 or older.CMV prophylaxis: Prevymis requires the applicable CMV serostatus and transplant criteria, transplant type, age, and duration documentation.Quetiapine XR: Document the qualifying indication, prerequisite generic alternatives or antipsychotic step therapy, and justification for concurrent CNS medications. Unjustified interacting or duplicate CNS therapy is a denial risk.Infliximab and biosimilars: Document the inflammatory disease diagnosis, prior conventional or biologic therapy, response or intolerance, and applicable biosimilar substitution or benefit criteria.Rinvoq: Document treatment history, including inadequate response or intolerance to a TNF inhibitor or other required systemic therapy, as applicable to the indication.Rubraca and oncology prerequisites: Document disease, biomarker, stage, prior treatment, and the required oncology regimen. Missing disease or biomarker evidence supports denial.Other denial risks: Requests may be denied for growth-hormone exclusion criteria, HES exclusion criteria, unconfirmed pulmonary hypertension or missing hemodynamics, absent platelet count or response, absent autoimmune or hereditary-disease confirmation, absent diagnostic or safety documentation, prohibited CYP3A4 inhibitor combinations, older-adult restrictions, incorrect combination or route, product or patient exclusions, program or indication exclusions, insufficient psoriasis severity or prior therapy, absent NTRK resistance mutation, absent ESR1-mutated breast-cancer evidence, absent fibrosis or response documentation, or specialty-drug medical criteria not being met.Required documentation: Include clinical and diagnostic records, laboratory and biomarker results, baseline and response measures, prior therapy and alternatives, safety and duration rationale, concomitant-medication justification, disease-specific evidence, specialty-drug medical-necessity documentation, IVIG and hematology records, Fulphila chemotherapy timing, growth-hormone records, hereditary angioedema testing, Increlex baseline height/IGF-1/GH testing, Imkeldi and Inbrija clinical documentation, KALYDECO combination-use documentation, KANJINTI indication and benefit documentation, ketoconazole medical-necessity documentation, Lytgobi FGFR2 documentation, Methylphenidate indication documentation, Modafinil sleep-disorder documentation, Northera response documentation, Nuedexta/Nuplazid documentation, Procrit laboratory documentation, Rezdiffra fibrosis and response documentation, and Rucaparib disease and biomarker documentation.